Literature DB >> 18523885

No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study.

Timothy R Rebbeck1, Antonis C Antoniou, Trinidad Caldes Llopis, Heli Nevanlinna, Kristiina Aittomäki, Jacques Simard, Amanda B Spurdle, Fergus J Couch, Lutecia H Mateus Pereira, Mark H Greene, Irene L Andrulis, Boris Pasche, Virginia Kaklamani, Ute Hamann, Csilla Szabo, Susan Peock, Margaret Cook, Patricia A Harrington, Alan Donaldson, Allison M Male, Carol Anne Gardiner, Helen Gregory, Lucy E Side, Anne C Robinson, Louise Emmerson, Ian Ellis, Jean-Philippe Peyrat, Joëlle Fournier, Philippe Vennin, Claude Adenis, Danièle Muller, Jean-Pierre Fricker, Michel Longy, Olga M Sinilnikova, Dominique Stoppa-Lyonnet, Rita K Schmutzler, Beatrix Versmold, Christoph Engel, Alfons Meindl, Karin Kast, Dieter Schaefer, Ursula G Froster, Georgia Chenevix-Trench, Douglas F Easton.   

Abstract

BACKGROUND: The transforming growth factor beta-1 gene (TGFB1) is a plausible candidate for breast cancer susceptibility. The L10P variant of TGFB1 is associated with higher circulating levels and secretion of TGF-beta, and recent large-scale studies suggest strongly that this variant is associated with breast cancer risk in the general population.
METHODS: To evaluate whether TGFB1 L10P also modifies the risk of breast cancer in BRCA1 or BRCA2 mutation carriers, we undertook a multi-center study of 3,442 BRCA1 and 2,095 BRCA2 mutation carriers.
RESULTS: We found no evidence of association between TGFB1 L10P and breast cancer risk in either BRCA1 or BRCA2 mutation carriers. The per-allele HR for the L10P variant was 1.01 (95%CI: 0.92-1.11) in BRCA1 carriers and 0.92 (95%CI: 0.81-1.04) in BRCA2 mutation carriers.
CONCLUSIONS: These results do not support the hypothesis that TGFB1 L10P genotypes modify the risk of breast cancer in BRCA1 or BRCA2 mutation carriers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18523885      PMCID: PMC2700286          DOI: 10.1007/s10549-008-0064-8

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  25 in total

1.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

Authors:  A Antoniou; P D P Pharoah; S Narod; H A Risch; J E Eyfjord; J L Hopper; N Loman; H Olsson; O Johannsson; A Borg; B Pasini; P Radice; S Manoukian; D M Eccles; N Tang; E Olah; H Anton-Culver; E Warner; J Lubinski; J Gronwald; B Gorski; H Tulinius; S Thorlacius; H Eerola; H Nevanlinna; K Syrjäkoski; O-P Kallioniemi; D Thompson; C Evans; J Peto; F Lalloo; D G Evans; D F Easton
Journal:  Am J Hum Genet       Date:  2003-04-03       Impact factor: 11.025

2.  Association of a T29-->C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese.

Authors:  M Yokota; S Ichihara; T L Lin; N Nakashima; Y Yamada
Journal:  Circulation       Date:  2000-06-20       Impact factor: 29.690

3.  The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

Authors:  Sunil R Lakhani; Marc J Van De Vijver; Jocelyne Jacquemier; Thomas J Anderson; Peter P Osin; Lesley McGuffog; Douglas F Easton
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

Review 4.  TGF-beta signaling in tumor suppression and cancer progression.

Authors:  R Derynck; R J Akhurst; A Balmain
Journal:  Nat Genet       Date:  2001-10       Impact factor: 38.330

5.  T29C polymorphism in the transforming growth factor beta1 gene and postmenopausal breast cancer risk: the Multiethnic Cohort Study.

Authors:  Loïc Le Marchand; Christopher A Haiman; David van den Berg; Lynne R Wilkens; Laurence N Kolonel; Brian E Henderson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-03       Impact factor: 4.254

6.  A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer.

Authors:  Alison M Dunning; Peter D Ellis; Simon McBride; Heidi L Kirschenlohr; Catherine S Healey; Paul R Kemp; Robert N Luben; Jenny Chang-Claude; Arto Mannermaa; Vesa Kataja; Paul D P Pharoah; Douglas F Easton; Bruce A J Ponder; James C Metcalfe
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

7.  Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study.

Authors:  Xiao-Ou Shu; Yu-Tang Gao; Qiuyin Cai; Larry Pierce; Hui Cai; Zhi-Xian Ruan; Gong Yang; Fan Jin; Wei Zheng
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

8.  The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk.

Authors:  Peter Krippl; Uwe Langsenlehner; Wilfried Renner; Babak Yazdani-Biuki; Gerald Wolf; Thomas C Wascher; Bernhard Paulweber; Babak Bahadori; Hellmut Samonigg
Journal:  Cancer Lett       Date:  2003-11-25       Impact factor: 8.679

9.  Transforming growth factor B1 T29C polymorphism and breast cancer risk in Japanese women.

Authors:  Asahi Hishida; Hiroji Iwata; Nobuyuki Hamajima; Keitaro Matsuo; Mitsuhiro Mizutani; Takuji Iwase; Shigeto Miura; Nobuhiko Emi; Kaoru Hirose; Kazuo Tajima
Journal:  Breast Cancer       Date:  2003       Impact factor: 4.239

10.  TGFB1 and TGFBR1 polymorphisms and breast cancer risk in the Nurses' Health Study.

Authors:  David G Cox; Kathryn Penney; Qun Guo; Susan E Hankinson; David J Hunter
Journal:  BMC Cancer       Date:  2007-09-11       Impact factor: 4.430

View more
  7 in total

1.  Association between the TNF-α-238G>A and TGF-β1 L10P Polymorphisms and Breast Cancer Risk: A Meta-Analysis.

Authors:  Jun Guo; Hua Meng; Jianming Pei; Miaozhang Zhu
Journal:  Breast Care (Basel)       Date:  2011-04-29       Impact factor: 2.860

Review 2.  Genetic susceptibility to breast cancer.

Authors:  Nasim Mavaddat; Antonis C Antoniou; Douglas F Easton; Montserrat Garcia-Closas
Journal:  Mol Oncol       Date:  2010-05-21       Impact factor: 6.603

3.  Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium.

Authors:  Annegien Broeks; Marjanka K Schmidt; Mark E Sherman; Fergus J Couch; John L Hopper; Gillian S Dite; Carmel Apicella; Letitia D Smith; Fleur Hammet; Melissa C Southey; Laura J Van 't Veer; Renate de Groot; Vincent T H B M Smit; Peter A Fasching; Matthias W Beckmann; Sebastian Jud; Arif B Ekici; Arndt Hartmann; Alexander Hein; Ruediger Schulz-Wendtland; Barbara Burwinkel; Frederik Marme; Andreas Schneeweiss; Hans-Peter Sinn; Christof Sohn; Sandrine Tchatchou; Stig E Bojesen; Børge G Nordestgaard; Henrik Flyger; David D Ørsted; Diljit Kaur-Knudsen; Roger L Milne; Jose I Arias Pérez; Pilar Zamora; Primitiva Menéndez Rodríguez; Javier Benítez; Hiltrud Brauch; Christina Justenhoven; Yon-Dschun Ko; Ute Hamann; Hans-Peter Fischer; Thomas Brüning; Beate Pesch; Jenny Chang-Claude; Shan Wang-Gohrke; Michael Bremer; Johann H Karstens; Peter Hillemanns; Thilo Dörk; Heli A Nevanlinna; Tuomas Heikkinen; Päivi Heikkilä; Carl Blomqvist; Kristiina Aittomäki; Kirsimari Aaltonen; Annika Lindblom; Sara Margolin; Arto Mannermaa; Veli-Matti Kosma; Jaana M Kauppinen; Vesa Kataja; Päivi Auvinen; Matti Eskelinen; Ylermi Soini; Georgia Chenevix-Trench; Amanda B Spurdle; Jonathan Beesley; Xiaoqing Chen; Helene Holland; Diether Lambrechts; Bart Claes; Thijs Vandorpe; Patrick Neven; Hans Wildiers; Dieter Flesch-Janys; Rebecca Hein; Thomas Löning; Matthew Kosel; Zachary S Fredericksen; Xianshu Wang; Graham G Giles; Laura Baglietto; Gianluca Severi; Catriona McLean; Christopher A Haiman; Brian E Henderson; Loic Le Marchand; Laurence N Kolonel; Grethe Grenaker Alnæs; Vessela Kristensen; Anne-Lise Børresen-Dale; David J Hunter; Susan E Hankinson; Irene L Andrulis; Anna Marie Mulligan; Frances P O'Malley; Peter Devilee; Petra E A Huijts; Rob A E M Tollenaar; Christi J Van Asperen; Caroline S Seynaeve; Stephen J Chanock; Jolanta Lissowska; Louise Brinton; Beata Peplonska; Jonine Figueroa; Xiaohong R Yang; Maartje J Hooning; Antoinette Hollestelle; Rogier A Oldenburg; Agnes Jager; Mieke Kriege; Bahar Ozturk; Geert J L H van Leenders; Per Hall; Kamila Czene; Keith Humphreys; Jianjun Liu; Angela Cox; Daniel Connley; Helen E Cramp; Simon S Cross; Sabapathy P Balasubramanian; Malcolm W R Reed; Alison M Dunning; Douglas F Easton; Manjeet K Humphreys; Carlos Caldas; Fiona Blows; Kristy Driver; Elena Provenzano; Jan Lubinski; Anna Jakubowska; Tomasz Huzarski; Tomasz Byrski; Cezary Cybulski; Bohdan Gorski; Jacek Gronwald; Paul Brennan; Suleeporn Sangrajrang; Valerie Gaborieau; Chen-Yang Shen; Chia-Ni Hsiung; Jyh-Cherng Yu; Shou-Tung Chen; Giu-Cheng Hsu; Ming-Feng Hou; Chiun-Sheng Huang; Hoda Anton-Culver; Argyrios Ziogas; Paul D P Pharoah; Montserrat Garcia-Closas
Journal:  Hum Mol Genet       Date:  2011-05-19       Impact factor: 6.150

Review 4.  Genetic susceptibility to triple-negative breast cancer.

Authors:  Kristen N Stevens; Celine M Vachon; Fergus J Couch
Journal:  Cancer Res       Date:  2013-03-27       Impact factor: 12.701

5.  Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers.

Authors:  Logan C Walker; Zachary S Fredericksen; Xianshu Wang; Robert Tarrell; Vernon S Pankratz; Noralane M Lindor; Jonathan Beesley; Sue Healey; Xiaoqing Chen; Dominique Stoppa-Lyonnet; Carole Tirapo; Sophie Giraud; Sylvie Mazoyer; Danièle Muller; Jean-Pierre Fricker; Capucine Delnatte; Rita K Schmutzler; Barbara Wappenschmidt; Christoph Engel; Ines Schönbuchner; Helmut Deissler; Alfons Meindl; Frans B Hogervorst; Martijn Verheus; Maartje J Hooning; Ans Mw van den Ouweland; Marcel R Nelen; Margreet Gem Ausems; Cora M Aalfs; Christi J van Asperen; Peter Devilee; Monique M Gerrits; Quinten Waisfisz; Csilla I Szabo; Douglas F Easton; Susan Peock; Margaret Cook; Clare T Oliver; Debra Frost; Patricia Harrington; D Gareth Evans; Fiona Lalloo; Ros Eeles; Louise Izatt; Carol Chu; Rosemarie Davidson; Diana Eccles; Kai-Ren Ong; Jackie Cook; Tim Rebbeck; Katherine L Nathanson; Susan M Domchek; Christian F Singer; Daphne Gschwantler-Kaulich; Anne-Catharina Dressler; Georg Pfeiler; Andrew K Godwin; Tuomas Heikkinen; Heli Nevanlinna; Bjarni A Agnarsson; Maria Adelaide Caligo; Håkan Olsson; Ulf Kristoffersson; Annelie Liljegren; Brita Arver; Per Karlsson; Beatrice Melin; Olga M Sinilnikova; Lesley McGuffog; Antonis C Antoniou; Georgia Chenevix-Trench; Amanda B Spurdle; Fergus J Couch
Journal:  Breast Cancer Res       Date:  2010-11-29       Impact factor: 6.466

6.  The L10P polymorphism and serum levels of transforming growth factor β1 in human breast cancer.

Authors:  Eva Taubenschuß; Erika Marton; Maurice Mogg; Barbara Frech; Lisa Ehart; Dana Muin; Martin Schreiber
Journal:  Int J Mol Sci       Date:  2013-07-24       Impact factor: 5.923

Review 7.  Two faces of TGF-beta1 in breast cancer.

Authors:  Joanna Magdalena Zarzynska
Journal:  Mediators Inflamm       Date:  2014-05-07       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.